Resolutions urging the Congress of the United States to update the Drug Addiction Treatment Act of 2000 and remove excessive training requirements mandated for obtaining a waiver to prescribe buprenorphine

194th Legislature (2025-2026) Introduced by Bruce Ayers

Bill H 3827 urges Congress to ease training rules for prescribing buprenorphine, boosting treatment access for opioid addiction and improving public health outcomes.

Resolutions reported favorably by committee and referred to the committee on House Steering, Policy and Scheduling

Purpose and Intent

Bill H 3827 is a resolution introduced in the Massachusetts General Court that urges the United States Congress to amend the Drug Addiction Treatment Act of 2000. The primary goal of the bill is to eliminate excessive training requirements that currently hinder healthcare providers from obtaining a waiver to prescribe buprenorphine, a medication used to treat opioid addiction.

Key Provisions

Update to the Drug Addiction Treatment Act of 2000: The bill calls for Congress to revise the existing law to remove the mandatory 8-hour training and examination that physicians must complete to prescribe buprenorphine.

Comparison with Other Schedule III Drugs: The bill highlights that other Schedule III drugs do not require similar training or a special “X license” from the DEA, arguing that the current requirements for buprenorphine are unnecessarily stringent.

Encouragement of Treatment Options: By reducing barriers to prescribing buprenorphine, the bill aims to promote the use of medically-assisted treatment (MAT) for opioid addiction, which has been shown to be effective in reducing dependence and withdrawal symptoms.

Impact

Healthcare Providers: The resolution is expected to facilitate easier access for physicians to prescribe buprenorphine, thereby increasing the availability of treatment for patients suffering from opioid use disorder.

Patients: Individuals struggling with opioid addiction may benefit from improved access to buprenorphine, potentially leading to better health outcomes and reduced overdose rates.

Public Health: The bill addresses a critical public health crisis, as the opioid epidemic has resulted in significant morbidity and mortality, with over 130 daily deaths attributed to opioid overdoses in the U.S.

Procedural Aspects

Introduced: The bill was introduced on February 27, 2025, by Representative Bruce J. Ayers.

Committee Referral: It has been referred to the committee on Veterans and Federal Affairs.

Hearing Schedule: A hearing for the bill has been rescheduled to November 13, 2025, from 1:00 PM to 3:50 PM, with a virtual option available.

Conclusion

Bill H 3827 seeks to address the opioid crisis by advocating for legislative changes that would streamline the process for prescribing buprenorphine. By removing unnecessary training requirements, the bill aims to enhance treatment accessibility for those affected by opioid addiction, ultimately contributing to improved public health outcomes.

Bill